The company’s quarterly revenue reached EUR 4,861 million, marking a 5% organic growth across all operating segments. Profitability gains were bolstered by the 5008X CAREsystem, now active in 227 U.S. clinics with over 600,000 treatments performed. Early data from the BEACON-US research initiative suggests the technology is improving patient outcomes, with specific clinical observations showing a 40% reduction in muscle cramps among patients using the new modality.

Operational efficiency remains a core focus, with the FME25+ transformation program yielding an additional EUR 67 million in savings during the quarter. The company completed its 2026 U.S. clinic optimization plan, closing approximately 100 locations to streamline the network. CEO Helen Giza emphasized that disciplined capital allocation, including a billion-euro share buyback program initiated in May, continues to drive long-term shareholder value despite currency headwinds and ongoing regulatory adjustments.